# A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

> **NCT05765812** · PHASE1,PHASE2 · RECRUITING · sponsor: **Debiopharm International SA** · enrollment: 116 (estimated)

## Conditions studied

- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Astrocytoma, Grade III

## Interventions

- **DRUG:** Debio 0123
- **DRUG:** Temozolomide
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT05765812
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-15
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05765812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05765812, "A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05765812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*